Hims & Hers Health, Inc. HIMS
This picture changes. Follow Hims & Hers Health, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Hims & Hers Health, Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 18 Jul 2026
Latest news check: 11 Aug 2026
General analysis — not personal advice.
HOLD
5/10
Confidence
Hold existing position and monitor margin trends together with FTC developments.
Strong revenue growth is offset by clear margin pressure and fresh regulatory risk, supporting a cautious stance after the Q2 report.
Market sentiment
5/10
↓
Trend: Declining
Sentiment has shifted to neutral-to-mildly negative due to margin concerns and regulatory uncertainty around FTC and GLP-1.
Price context
The stock closed at 31.77 USD after a 13 % drop on the FTC news and a further 5–6 % decline post-Q2 report. The level reflects the balance between ongoing subscriber growth and near-term profitability uncertainty.
Risk assessment
7/10
Dilution:
Medium
Convertible notes and recent issuance
Jurisdiction:
Low
Primarily US, UK and Australia
Execution:
Medium
Eucalyptus integration and margin targets
Recent changes
- The report shows continued revenue growth but clear margin decline plus an FTC lawsuit that raises uncertainty.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Hims & Hers is a digital health platform connecting consumers with licensed providers via telehealth. The company offers subscription-based treatments for weight loss (GLP-1), hair loss, sexual health and mental health. Operations are expanding internationally through acquisitions with positive operating cash flow.
Sector:
Digital health platform
Type:
Tech
Next report
3 Nov 2026
Q3
Catalysts
Oct 2026
Q3 report
Medium
Nov 2026
Eucalyptus integration
High
Horizon:
Bull case
Strong subscriber growth and international expansion through Eucalyptus continue to support top-line momentum.
Bear case
Shift to branded drugs and regulatory risks compress margins and increase uncertainty.
Signal rationale (informational)
Strong revenue growth is offset by clear margin pressure and fresh regulatory risk, supporting a cautious stance after the Q2 report.
Recent news
- Q2 report on 10 August showed revenue of 753 MUSD but an 86 MUSD net loss and gross margin falling to 64 %. FTC filed suit on 29 July regarding billing and data sharing. The company is shifting its weight-loss offering to branded GLP-1 drugs and integrating Eucalyptus.
Key figures
Revenue
Q2 2026
USD 753M
EBITDA
Q2 2026
USD 60.3M
Net income
Q2 2026
USD -86.3M
Cash
Q2 2026
USD 610M
Gross margin
Q2 2026
64.0%
Price & valuation
Last close
USD 30.51
1 week
-3.6 %
3 months
+26.4 %
Exchange
NYSE
Type
Technology
Sector
Digital health platform
This picture changes. Follow Hims & Hers Health, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.